Synergistic effects of Nrf2 inhibitor, brusatol treatment in combination with lapatinib, a selective HER2 tyrosine kinase inhibitor in HER2-positive cancers
Ziyin Tian(Henan Medical University), Yun Yang(Tongji University)
Cited by 2
Related Papers
The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
|Heliyon|2022|23
Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer
|Biochemical and Biophysical Research Communications|2016|18